alendronate sodium
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Osteopenia
Conditions
Osteopenia, Osteoporosis
Trial Timeline
Feb 1, 2006 → Apr 1, 2009
NCT ID
NCT00504166About alendronate sodium
alendronate sodium is a approved stage product being developed by Merck for Osteopenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00504166. Target conditions include Osteopenia, Osteoporosis.
What happened to similar drugs?
4 of 9 similar drugs in Osteopenia were approved
Approved (4) Terminated (0) Active (5)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00504166 | Approved | Completed |
Competing Products
18 competing products in Osteopenia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Teriparatide + Zoledronic Acid | Eli Lilly | Approved | 43 |
| zoledronic acid | Novartis | Phase 3 | 40 |
| zoledronic acid vs pamidronate | Novartis | Approved | 43 |
| Zoledronic Acid + Placebo | Novartis | Phase 3 | 40 |
| BPS804 20mg/Kg + Placebo to 20mg/Kg BPS804 | Novartis | Phase 2 | 35 |
| Placebo + ibandronate [Bonviva/Boniva] | Roche | Approved | 43 |
| ibandronate [Bonviva/Boniva] + Placebo | Roche | Phase 3 | 40 |
| Romosozumab + Placebo | Amgen | Phase 1 | 29 |
| Placebo + AMG 167 | Amgen | Phase 1 | 29 |
| AMG 167 + Placebo | Amgen | Phase 1 | 29 |
| Romosozumab + Placebo | Amgen | Phase 1 | 29 |
| Denosumab | Amgen | Phase 3 | 40 |
| Romosozumab + Placebo | Amgen | Phase 1 | 29 |
| Dasatinib 100 Mg Oral Tablet | Novo Nordisk | Phase 2 | 39 |
| RN564 | Pfizer | Phase 1 | 29 |
| risedronate + alendronate | Sanofi | Phase 1 | 29 |
| Menostar (Estradiol, BAY86-5435) + Raloxifene | Bayer | Phase 3 | 37 |
| tibolone + raloxifen | Organon | Approved | 37 |